GBLX GB Sciences Inc (PK)

SEC File Number: 000-55462

CUSIP Number: 361544109

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 12b-25

 

Notification of Late Filing

 

(Check One):

 

☐ Form 10-K ☐ Form  20-F☐ Form  11-K ☒ Form 10-Q ☐ Form 10-D 

☐ Form N-SAR☐ Form N-CSR 

 

For Period Ended:         September 30, 2024

 

☐Transition  Report on Form  10-K  

☐Transition  Report  on Form  20-F  

☐Transition  Report on Form 11-K  

☐Transition  Report  on  Form  10-Q  

☐Transition Report on Form N-SAR  

For the Transition Period Ended: _______________________  

 

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

Part I - Registrant Information

 

GB Sciences, Inc.

Full Name of Registrant

N/A

Former Name if Applicable

9205 W. Russell Road, Suite 240

Address of Principal Executive Office (Street and Number)

Las Vegas, Nevada 89148

City, State and Zip Code

 

 

Part II - Rules 12b-25(b) and (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box, if appropriate)

 

☒(a)The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; 

 

☐ (b)The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K, Form N- SAR, or Form N-CSR, or portion thereof will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or subject distribution report on Form 10-D, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and  

 

☐(c)The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.  

 

Part III - Narrative

 

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof could not be filed within the prescribed period.

 

GB Sciences, Inc. (the “Company”) has determined that it is unable to file its Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2024, within the prescribed time period without unreasonable effort or expense. During the quarter, the Company’s principle financial officer who was also the Company’s principle accounting officer unexpectedly passed away. This event along with other circumstances resulted in the Form 10-Q not being able to be compiled and filed within the customary time period.  

 

Part IV - Other Information

 

(1)Name and telephone number of the person to contract in regard to this notification. 

 

Gary R. Henrie		(307)		200-9415
(Name)		(Area Code)		(Telephone Number)

 

(2)Have all other periodic reports required under section 13 or 15(d) of the Securities Exchange Act of 1934 or section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed?  If the answer is no, identify report(s). 

 

☐ Yes ☒ No The Company’s Quarterly Report for the fiscal quarter ending June 30, 2024, has not been filed.

 

 

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?   

 

☐ Yes ☒ No

 

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

 

GB Sciences, Inc.

(Name of Registrant as specified in charter)

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

Date:  November 14, 2024	By:/s/ Andrea Small-Howard
	Andrea Small-Howard, CEO

 

 

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

 

 

ATTENTION

Intentional misstatements or omissions of fact constitute federal criminal violations (See 18 U.S.C. 1001).

 

---